Clinical trial
Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely…
NCT00191568 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191568 |
|---|---|
| Title | Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer |
| Official title | A Phase II Trial of Adjuvant Treatment With Gemcitabine and Oxaliplatin Followed by Concomitant Gemcitabine and Radiation Therapy in Patients With Resected Pancreatic Adenocarcinoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Neoplasms |
| Intervention type | Drug, Procedure |
| Interventions | Gemcitabine, Oxaliplatin, Radiotherapy |
| Enrollment | 45 |
| Start date | Oct 1, 2002 |
| Completion | May 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Oct 19, 2007 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: